Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
D000477:Alkylating Agents / Q000627:therapeutic use; D006585:Altretamine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004351:Drug Resistance; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014227:Triazines / Q000627:therapeutic use*
D000477:Alkylating Agents; D014227:Triazines; D006585:Altretamine